290 related articles for article (PubMed ID: 28062555)
1. Antibody Therapeutics Targeting Aβ and Tau.
Gallardo G; Holtzman DM
Cold Spring Harb Perspect Med; 2017 Oct; 7(10):. PubMed ID: 28062555
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
4. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
5. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
6. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
Boutajangout A; Wisniewski T
Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic approaches for Alzheimer's disease.
Wisniewski T; Goñi F
Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
[TBL] [Abstract][Full Text] [Related]
8. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y; Liu Y; Wang Z; Jiang Y
Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
[TBL] [Abstract][Full Text] [Related]
11. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
12. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
13. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
14. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson EM
J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
[TBL] [Abstract][Full Text] [Related]
16. Tau immunization: a cautionary tale?
Mably AJ; Kanmert D; Mc Donald JM; Liu W; Caldarone BJ; Lemere CA; O'Nuallain B; Kosik KS; Walsh DM
Neurobiol Aging; 2015 Mar; 36(3):1316-32. PubMed ID: 25619661
[TBL] [Abstract][Full Text] [Related]
17. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
[TBL] [Abstract][Full Text] [Related]
19. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
[TBL] [Abstract][Full Text] [Related]
20. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
Huber CM; Yee C; May T; Dhanala A; Mitchell CS
J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]